CCR5 Blockade Shows Prevention of Alopecia Areata Development as Well as Improvement of Alopecia Areata

    September 2017 in “ ˜The œjournal of investigative dermatology/Journal of investigative dermatology ”
    Taisuke Ito, Tomoko Suzuki, Shinsuke Nakazawa, Toshiharu Fujiyama, Y. Tokura
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice. Our plain-language summary of this paper — not a Tressless recommendation.
    The study from October 1, 2017, demonstrated that the CCR5 inhibitor Maraviroc, originally an HIV drug, was effective in treating alopecia areata (AA) in C3H/HeJ mice. Mice treated with 330µg/day of Maraviroc for 28 days showed significant improvement, with 4 out of 5 mice exhibiting hair regrowth after 2 weeks. The treatment led to a decrease in CD4+CCR5+ and CD8+CCR5+ T cells in the affected areas and reduced the chemotactic activity of CD4+ lymph node cells. The findings suggest that CCR5 blockade can both prevent the onset of AA and improve existing hair loss lesions.
    Discuss this study in the Community →